Arecor Therapeutics (LSE:AREC), the Cambridge-based drug formulation specialist, has been one of the busier small biotech names on the FTSE AIM All Share index this autumn. On 15 October 2026 it announced patents covering its concentrated ultra-rapid insulins, following a fundraising of up to £5.13 million launched alongside interim results on 30 September and a series of Shareholder notifications in October.

What the company does

Arecor develops improved versions of existing medicines using its proprietary Arestat formulation technology platform, which is designed to make therapeutic proteins and peptides more stable, faster-acting or easier to deliver. Its lead in-house focus is diabetes, including AT278, a concentrated ultra-rapid-acting insulin intended for people with high insulin needs and for use in miniaturised insulin pumps and automated insulin delivery (AID) systems. Alongside its own pipeline, the company works with pharmaceutical partners under formulation and licensing arrangements that can generate fees and milestones.

Latest developments

The October Patent announcement relates to concentrated ultra-rapid insulin formulations, an area central to the AT278 programme. In August 2026 the company said AT278 data had been published in a peer-reviewed journal. Intellectual property protection is important for a Business of this kind because the value of reformulated medicines depends on exclusivity and on the ability to license that exclusivity to partners.

The fundraising announced on 30 September comprised a placing run through an accelerated bookbuild, followed by a retail offer to raise up to £130,000, the result of which was announced on 7 October. A half-year results investor presentation followed on 8 October, and several holding in company notices were published as the shareholder register changed after the raise.

Financial picture

According to the interim results, Revenue for the six months to 30 June 2026 fell to £0.2 million from £1.0 million a year earlier, while Research and Development costs increased to £1.9 million from £1.3 million. The loss after tax widened to £3.0 million from £2.0 million. Cash at the period end was £3.2 million, compared with £1.9 million a year earlier, before the post-period fundraising. The company also said partnering discussions for an insulin and AID combination had reached term sheet stage. As a development-stage company, Arecor does not pay a dividend.

Sector and index context

Arecor competes in a crowded diabetes market dominated by large insulin manufacturers, but its strategy is to partner with such groups and with device makers rather than compete head-on. Interest in automated insulin delivery and smaller wearable pumps has grown, which could increase Demand for concentrated, fast-acting insulins. On the FTSE AIM All Share Index, Arecor is a small-cap life sciences stock, a segment that has faced difficult funding conditions and in which share prices can be volatile around financing and clinical news.

Key risks

The company remains loss-making and dependent on external funding, so further Capital raises could dilute existing shareholders. Its commercial success relies on securing and executing partnerships, and term sheet discussions may not lead to signed agreements. Clinical, regulatory and Manufacturing hurdles remain for AT278, and low revenue in the first half shows how lumpy partner income can be.

What to watch next

Investors will focus on whether the insulin and AID partnering talks result in a definitive agreement, further progress on AT278 development, any new formulation deals with pharmaceutical partners and the company's cash runway following the autumn fundraising. A trading update ahead of full-year results would typically come in early 2027.